This well-conducted review found that hypomethylating agents, particularly 5-azacitidine, improved survival and other outcomes compared with conventional care, but were associated with significant adverse events. These conclusions are likely to be reliable.
Included trials assessed 5-azacitidine and decitabine. Control interventions consisted of best supportive care in three studies and either best supportive care, low-dose cytarabine or intensive chemotherapy in the other. Median age ranged from 67 to 70 years. In three trials at least 70% of patients were considered to have high-risk myelodysplastic syndrome according to the International Prognostic Scoring System. In the other study fewer than half of the patients were assessed using these criteria and half were considered high-risk.
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
Two reviewers independently assessed study quality based on criteria of allocation concealment, allocation generation and blinding. Disagreements were resolved through referral to a third reviewer.
Data extraction
Two reviewers independently extracted data to calculate relative risks (RR) for dichotomous data or hazard ratios (HR) for time to event data, together with 95% confidence intervals (CIs). Authors were contacted for additional information, where necessary. Disagreements were resolved through referral to a third reviewer.
Methods of synthesis
Summary relative risks and hazard ratios were estimated using the Peto fixed-effect model in the absence of heterogeneity and DerSimonian and Laird random-effects model where there was heterogeneity. Heterogeneity was assessed using X 2 and I 2 . Sensitivity analyses were used to assess the effect of study quality on effect estimates. The effect of drug type was assessed using mixed-effect meta-regression.
